Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, November 1998, p. 2836-2840, Vol. 42, No. 11
Laboratoire de Bactériologie,
Hôpital Pellegrin, 33076 Bordeaux Cedex,
France,1 and
The Romark Institute
for Medical Research, Tampa, Florida2
Received 18 March 1998/Returned for modification 17 June
1998/Accepted 20 August 1998
Nitazoxanide, a thiazolide compound, and its desacetyl derivative,
tizoxanide, have antimicrobial properties against anaerobic bacteria,
as well as against helminths and protozoa. Because the treatment of
Helicobacter pylori infection may be jeopardized by
metronidazole resistance, nitazoxanide and tizoxanide were tested in
vitro against these bacteria. The MICs of these two compounds were
determined by agar dilution and were compared to those of
metronidazole. Exposure to subinhibitory concentrations of nitazoxanide
was also carried out by the method of Szybalski (W. Szybalski and V. Bryson, J. Bacteriol. 64:489-499, 1952). The MICs of
nitazoxanide and tizoxanide for 103 strains ranged from 0.25 to 8 µg/ml, with the MIC at which 50% of strains are inhibited
(MIC50) being 1 µg/ml and the MIC90 being 4 µg/ml, and no resistant strain was detected, whereas strains
resistant to metronidazole were detected. When 10 strains were
successively subcultured on medium containing nitazoxanide, no
significant change in the MICs of this compound was observed. A pilot
study of nitazoxanide for the treatment of H. pylori
infection was carried out with 86 patients in association with 20 mg of
omeprazole. An eradication rate of 83% (95% confidence interval, 64%
to 94%) was obtained in a per-protocol analysis in the group receiving 1 g of nitazoxanide orally twice daily, and a few side effects were observed. The failures could not be explained by the selection of
resistant strains since the MICs of nitazoxanide were similar for six
pairs of isolates (proven to be the same strain by random amplified
polymorphic DNA analysis in four cases) cultured before and after
the treatment failure. Nitazoxanide exhibits good antimicrobial activity against H. pylori without the
problem of acquired resistance which is encountered with metronidazole
and has been demonstrated to have a satisfactory effect
in a dose-ranging pilot study. It is therefore a good candidate to be
included in treatment regimens aimed at the eradication of H. pylori.
Fifteen years after the discovery of
Helicobacter pylori, the eradication of this organism has
become the aim of treatments for the cure of most gastroduodenal
diseases, especially peptic ulcer and low-grade mucosa-associated
lymphoid tissue lymphoma (1). The most effective regimens
associate an antisecretory drug, in particular, a proton pump inhibitor
given at a double dose with two of the following antibiotics for 7 days: metronidazole, clarithromycin, and amoxicillin (9).
The metronidazole-clarithromycin combination has the advantage that 250 mg of clarithromycin twice daily (b.i.d.) instead of 500 mg b.i.d. can
be used when clarithromycin is associated with amoxicillin, limiting
the side effects and cost (20). However, resistance to
metronidazole, which is more frequent than resistance to
clarithromycin, jeopardizes the success of this regimen
(11).
Different methods with limited correlation are used to determine
H. pylori susceptibility to metronidazole;
nevertheless, an association between resistance and treatment
failure is found in most studies. Recently, in a large
multicenter study performed in Europe, a cure rate of 95% was found
when the strains were susceptible to metronidazole and a cure rate of
76% was found when the strains were resistant to metronidazole (MIC,
>8 µg/ml, as determined by the agar dilution method)
(13). When the combination of metronidazole-amoxicillin is
used, the difference is even more striking. In a study in which the
MICs were also determined by agar dilution, the cure rates were 90 and
45%, respectively (2). These observations have led to a
search for a compound with the same properties as metronidazole but
without the problem of resistance.
Nitazoxanide is a thiazolide (nitrothiazolamide) compound. Its
structure is 2-(acetolyloxy)-N-(5-nitro-2-thiazolyl)
benzamide (15) (Fig. 1).
The active compound in vivo is its desacetyl derivative,
tizoxanide. Antimicrobial properties of nitazoxanide have been shown
against helminths, protozoa (cryptosporidia, microsporidia, trichomonas, entamoeba, giardia) (3), and anaerobic bacteria (4).
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Nitazoxanide, a Potential Drug for Eradication of
Helicobacter pylori with No Cross-Resistance to
Metronidazole
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
View larger version (8K):
[in a new window]
FIG. 1.
Structure of nitazoxanide.
The aim of this study was to test the susceptibilities of H. pylori strains to nitazoxanide and tizoxanide in comparison to those to metronidazole and to determine the MICs before and after multiple passages on a gradient of nitazoxanide. The results of a pilot study with nitazoxanide administered to humans are also reported.
| |
MATERIALS AND METHODS |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
Strains. H. pylori strains were isolated in our laboratory from biopsy specimens obtained from patients with duodenal ulcer or nonulcer dyspepsia consulting different gastroenterologists in France and not having received previous eradication treatment (103 randomly selected strains). In addition, 10 French strains for which MICs of nitazoxanide were high and six pairs of isolates obtained in Egypt before and after a failure of treatment with omeprazole-nitazoxanide were also included.
Briefly, the biopsy specimens were ground and plated on Wilkins Chalgren agar (Oxoid, Basingstoke, Hampshire, United Kingdom) enriched with 10% human blood and containing vancomycin, cefsulodin, trimethoprim, and actidione, as well as on a nonselective medium, Columbia blood agar and pylori agar (bioMérieux, Marcy l'Etoile, France), a commercially available selective medium. The plates were incubated in a microaerobic atmosphere in a jar (GasPak jar without catalyst) for up to 10 days. The colonies were identified by positive catalase, urease, and oxidase tests as well as morphology. The strains were maintained frozen at
70°C before testing.
RAPD testing.
The six pairs of isolates obtained before and
after treatment failure were compared by random amplified polymorphic
DNA (RAPD) testing. Briefly, genomic DNA was obtained by boiling
suspensions of H. pylori with a turbidity equivalent to
that of a McFarland no. 5 standard. Amplification was carried out in a
25-µl volume containing 5 µl of H. pylori
suspension, 67 mM Tris-HCl (pH 8.8), 16 mM
(NH4)2SO4, 0.01% Tween 20, 1.5 mM
MgCl2, a 0.4-mM concentration of a deoxynucleoside
triphosphate mixture, a 5-µM concentration of primer, 1 U of
Taq DNA polymerase (Eurobio, Les Ulis, France), and
sterilized water. Each reaction mixture was overlaid with 50 µl of
mineral oil. Primer OPH8 (5'-GAA ACA CCC C-3'; Bioprobe Systems,
Montreuil, France) was used. A Perkin-Elmer (Norwalk, Conn.) 480 thermal cycler was used for amplification. The cycling program was
composed of 1 cycle at 94°C for 10 min; 40 cycles of 94°C for 1 min, 36°C for 1 min, and 72°C for 1 min; and a final incubation at
72°C for 10 min. Then, 20-µl aliquots of the PCR products were
separated by electrophoresis in 1.2% agarose gels containing 1 µg of
ethidium bromide per ml, and the gel was photographed under UV light.
The DNA of 
X174 HaeIII and a 1-kb DNA ladder (Promega,
Madison, Wis.) were used as size markers in all gels.
Determination of MICs. MICs were determined by an agar dilution method. Briefly, a suspension with a turbidity equivalent to that of a McFarland no. 3 standard (approximately 109 CFU/ml) was prepared from a 48-h culture on agar. The medium used was Wilkins Chalgren agar enriched with 10% sheep blood and Polyvitex. An appropriate dilution of the compounds (nitazoxanide, tizoxanide, or metronidazole) was added at concentrations ranging from 0.03 to 128 µg/ml. The media were prepared extemporaneously, but no anaerobic preincubation was performed. Nitazoxanide and tizoxanide were obtained from the Romark Institute for Medical Research, Tampa, Fla. The compounds are not commercially available in the United States. In order to test the impact of an acidic medium, the pH was adjusted to 6.5 with a surface microelectrode in another set of experiments. Incubation was performed under the same conditions used for culture. The MIC was defined as the lowest concentration of antimicrobial agent inhibiting the total growth of bacteria. Resistance was considered when the metronidazole MIC was greater than 8 µg/ml.
Exposure to subinhibitory concentrations of nitazoxanide. A continuous progressive concentration of nitazoxanide or metronidazole was obtained in agar plates by the method of Szybalski and Bryson (19). The gradients tested ranged from 0 to 1 mg/liter and from 0 to 15 mg/liter.
Ten strains from France for which the MICs were the highest were tested. Subcultures were repeated 10 times for each strain, and incubation lasted 7 days each time. Between the different passages, the strains were grown on a medium without antibiotic. MICs were determined before passaging and after 5 and 10 passages of the strains while they were in contact with nitazoxanide or metronidazole.Pilot study of nitazoxanide in the treatment of H. pylori infections. An open, phase II dose-ranging study was carried out in Egypt with patients seeking treatment for dyspepsia. Three dosages of 500 mg b.i.d. for 14 days, 500 mg three times daily for 7 days, and 1 g b.i.d. for 7 days were tested, always with 20 mg of omeprazole/day.
At entry, H. pylori infection was diagnosed by histology, culture, and serology by an enzyme-linked immunosorbent assay with blood for the detection of immunoglobulin G antibodies (Quickvue; Quidel, San Diego, Calif.). Patients were included if at least two tests were positive. The same tests except serology were repeated at least 4 weeks after the end of the treatment. In addition, a [13C]urea breath test (Meretek Diagnostics, Inc., Houston, Tex.) was performed with a significant number of patients after treatment. The patient was considered to be cured of H. pylori infection if all tests were negative. Adverse events were also recorded. The calculation of the eradication rate was performed per protocol analysis only for patients who completed the study protocol and for whom H. pylori tests results were available.| |
RESULTS |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
The cumulative MICs of nitazoxanide, tizoxanide, and metronidazole for 103 strains of H. pylori isolated in France are presented in Fig. 2. Nitazoxanide and tizoxanide had similar potencies which were not affected by resistance to metronidazole. The MICs at which 50% of strains are inhibited (MIC50s), MIC90s, and the range of MICs are presented in Table 1. The MICs were also determined for 30 strains at pH 6.5, and the same results were obtained.
|
|
When 10 strains were subcultured 10 times on gradients of nitazoxanide or metronidazole as described by Szybalski and Bryson (19) (Szybalski gradients), it was not possible to detect a significant increase in the MICs of nitazoxanide (Table 2). In contrast, a significant increase in the MICs of metronidazole was observed after contact with either metronidazole or nitazoxanide. The exception was when the strain was already resistant to metronidazole (strains 41, 158, 135, 271, and 306).
|
Furthermore, strains isolated from patients with posttreatment failure during the phase II clinical trial in Egypt were tested. The MICs of nitazoxanide, tizoxanide, and metronidazole for these strains were within 1 dilution of the values observed for the pretreatment strains tested (Table 3). Indeed when pre- and posttreatment isolates were compared by RAPD analysis, only four of the six pairs (pairs A, B, D, and E) turned out to be the same strain (Fig. 3).
|
|
Eighty-six patients were analyzed per protocol, including 24 with peptic ulcers and 62 with nonulcer dyspepsia. The results of this pilot study are presented in Table 4. Because of the small number of patients, they were not analyzed according to initial clinical diagnosis. The highest eradication rate was obtained in group 3 (83%). The difference was statistically significant when the eradication rate for group 3 was compared to that for group 2 (58%; P = 0.037) and approached statistical significance when the eradication rate for group 3 was compared to that for group 1 (65%; P = 0.095). Minor side effects were reported by a total of 15 patients. No reason for the higher number of side effects observed in groups 1 and 2 was found.
|
| |
DISCUSSION |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
Metronidazole is an attractive compound for use in the treatment of H. pylori infection because it is secreted in the stomach (21) and reaches high concentrations. Furthermore, its activity is not affected by a decrease in pH (10). However, when given as the only antimicrobial agent, acquired resistance is so frequent that the use of metronidazole in association with another drug is mandatory (8). In addition, the high frequency of primary resistance observed makes its use questionable. In developing countries such as Africa, where most of the population is infected with H. pylori, the prevalence of resistance to metronidazole is high and virtually all strains are resistant (5). In developed countries, the prevalence varies between 10 and 50% (6). While there is some controversy with regard to the method to be used to test for metronidazole resistance and the possible recovery of strains with false resistance, a global decrease in the efficacies of treatment regimens containing metronidazole is noted when strains are resistant to this compound compared to the efficacies of these regimens when strains are susceptible (12). Nonetheless, the eradication rate of triple therapies that include metronidazole is still in the range of 50 to 70% due to the activity of the second antibiotic that is present.
A compound similar to metronidazole but without the problem of resistance is needed for the treatment of H. pylori infection. Nitazoxanide seems to fulfill this requirement. We have found that its MICs are in the range of those of metronidazole for the strains which are considered susceptible to metronidazole. Even after long-term exposure of H. pylori strains to nitazoxanide, the MICs are not modified. Ten H. pylori strains were exposed to nitazoxanide and metronidazole in vitro for a total of 2 months, which represents a large number of successive generations of the bacteria, and no resistance was selected.
We have also tested H. pylori strains isolated from patients before treatment and after failure of treatment with nitazoxanide. Four pairs proved to be the same strain, while for the two other pairs we can hypothesize that the patient was infected with two different strains. Again, the selection of resistant mutants was not the cause of failure, and the MICs for the strains were similar before and after the course of treatment.
Nitazoxanide has been shown to have a dose-dependent effect on DNA synthesis. This property has also been found with parasites, but the exact mechanism of action of nitazoxanide is not known, nor is the mechanism of action of metronidazole. Studies show that the nitro group of the antibiotic must be reduced in the target organism (17), and nitazoxanide can be reduced at a redox potential at least 3.3 times lower than that observed for metronidazole (19a).
Nitazoxanide has proved to be nontoxic (14), and its pharmacokinetics have been determined in healthy volunteers (18). The only measurable species in plasma was desacetyl nitazoxanide (tizoxanide), which reached a maximum concentration of 1.9 mg/liter (range, 1.1 to 2.5 mg/liter) 2 to 6 h after ingestion of a single dose of 500 mg of nitazoxanide. For this reason we also tested tizoxanide and found that it has the same activity as nitazoxanide, in contrast to results obtained for anaerobic bacteria except those of the Bacteroides fragilis group (4). No data on the concentration of tizoxanide in gastric juice are currently available.
The high concentration of metronidazole obtained in gastric juice can be explained by the pH partition hypothesis; i.e., weak bases are trapped in acidic compartments such as the stomach (16). When H+ secretion is highly suppressed (when 40 g of omeprazole b.i.d. is used), the concentration of metronidazole in the stomach approaches the range of the concentration in blood (7). Therefore, metronidazole should be used without acid suppression. However, the almost constant development of resistance to metronidazole in vivo renders its use impossible. To avoid the development of resistance, a second antibiotic must be added, with studies recommending the use of either amoxicillin or clarithromycin, both of which have pH-dependent activities. The further addition of an antisecretory drug therefore becomes mandatory. Tizoxanide is also a weak base, and it is most likely that the same phenomenon that occurs with metronidazole occurs with tizoxanide. However, because we are not faced with the problem of the development of resistance, it is possible to use only a low dose of antisecretory drug essentially with the aim of relieving pain, and no other antibiotic is needed.
In the dose-ranging pilot study, nitazoxanide at 1 g/day given with 20 mg of omeprazole led to a promising rate of eradication of 83%, per protocol. Among the antimicrobial agents tested, only amoxicillin and clarithromycin could achieve such a high eradication rate when used with a proton pump inhibitor, but for a treatment duration of 2 weeks. Furthermore, with the dual therapy with amoxicillin, such good results have not been reproduced in all centers (1), the average rate of success being in the range of 50%. Similarly, dual therapy with clarithromycin used high doses (1.5 g/day), which led to taste disturbances. Among the treatment failures, a large proportion of resistant strains was detected (22). In contrast, this problem does not seem to occur with nitazoxanide.
In conclusion, nitazoxanide was a well-tolerated compound, and its use was able to achieve a high rate of eradication of H. pylori when it was administered with omeprazole for 7 days. Its microbiological characteristics are close to those of metronidazole, but resistance could not be observed, despite in vivo exposure during the course of treatments and long-term in vitro exposure.
| |
ACKNOWLEDGMENTS |
|---|
We thank IPSEN Laboratories (Paris, France) and Romark Laboratories (Tampa, Fla.) for support for this study and S. M. Kabil from the Cairo GIT & Liver Center in Cairo, Egypt, for his contribution to the study of the effects of nitazoxanide in the treatment of H. pylori in Egypt.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Laboratoire de Bactériologie, Hôpital Pellegrin, 33076 Bordeaux Cedex, France. Phone: 33 5 56 79 59 10. Fax: 33 5 56 79 60 18. E-mail: francis.megraud{at}chu-aquitaine.fr.
| |
REFERENCES |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
| 1. | Anonymous. 1997. The report of the Digestive Health Initiative International Update Conference on Helicobacter pylori. Gastroenterology 113:54-58. |
| 2. | Bouchard, S., C. Birac, H. Lamouliatte, S. Forestier, and F. Mégraud. 1996. Correlation between the MICs of metronidazole on H. pylori strains and the outcome of a lansoprazole-amoxicillin-metronidazole therapy. Gut 39(Suppl. 2):A6. |
| 3. | Doumbo, O., J. F. Rossignol, E. Pichard, H. Traore, M. M. Dembele, M. Diakite, F. Traore, and A. D. Diallo. 1997. Nitazoxanide in the treatment of cryptosporidiosis in 24 AIDS patients with chronic diarrhea in Mali. Am. J. Trop. Med. Hyg. 56:637-639. |
| 4. |
Dubreuil, L.,
X. Houcke,
Y. Mouton, and J. F. Rossignol.
1996.
In vitro evaluation of nitazoxanide and tizoxanide against anaerobes and aerobic organisms.
Antimicrob. Agents Chemother.
40:2266-2270 |
| 5. | Glupczynski, Y., L. Boudeaux, C. De Perez, D. Devos, T. Devreker, B. Balegamire, H. Goossens, C. Van den Borre, and J.-P. Butzler. 1991. Prevalence of Helicobacter pylori in rural Kivu, eastern Zaire: a prospective endoscopic study. Eur. J. Gastroenterol. Hepatol. 3:449-455. |
| 6. | Glupczynski, Y., and the European Study Group on Antibiotic Susceptibility of H. pylori. 1992. Results of a multicentre European survey in 1991 of metronidazole resistance in H. pylori. Eur. J. Clin. Microbiol. Infect. Dis. 11:777-781[Medline]. |
| 7. | Goddard, A. F., M. J. Jessa, D. A. Barrett, P. N. Shaw, J. P. Idström, C. Cederberg, and R. C. Spiller. 1996. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 111:358-367[Medline]. |
| 8. |
Goodwin, C. S.,
B. J. Marshall,
E. D. Blincow,
D. H. Wilson,
S. Blackbourn, and M. Philipps.
1988.
Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies.
J. Clin. Pathol.
41:207-210 |
| 9. | Lind, T., S. Veldhuyzen Van Zanten, P. Unge, T. Lind, R. Spiller, E. Bayerdörffer, C. O'Morain, K. Dev Bardhan, M. Bradette, N. Chiba, and M. Wrangstadh. 1996. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the Mach 1 study. Helicobacter 1:138-144[Medline]. |
| 10. |
McNulty, C. A. M.,
J. C. Dent,
G. A. Ford, and S. P. Wilkinson.
1988.
Inhibitory antimicrobial concentration against Campylobacter pylori in gastric mucosa.
J. Antimicrob. Chemother.
22:729-738 |
| 11. | Mégraud, F. 1997. Resistance of Helicobacter pylori to antibiotics. Aliment. Pharmacol. Ther. 11(Suppl. 1):43-53. |
| 12. |
Megraud, F., and H. P. Doermann.
1998.
Clinical relevance of resistant strains of Helicobacter pylori. A review of current data.
Gut
43:S61-S65 |
| 13. |
Mégraud, F.,
N. Lehn,
T. Lind,
E. Bayerdörffer,
C. O'Morain,
R. C. Spiller,
P. Unger,
S. Veldhuyzen Van Zanten,
M. Wrangstadh, and A. Burman.
1997.
The MACH 2 study Helicobacter pylori resistance to antimicrobial agents and its influence on clinical outcome.
Gastroenterology
112:A216.
|
| 14. |
Murphy, J., and J. C. Friedman.
1985.
Preclinical toxicology of nitazoxanidea new antiparasitic compound.
J. Appl. Toxicol.
5:49-52[Medline].
|
| 15. | Rossignol, J. F., and R. Cavier. 1975. New derivative of 2-benzamido-5-nitrothiazoles. Chem. Abstr. 83:28216n. |
| 16. |
Shore, P. A.,
B. B. Brodie, and C. A. M. Hogben.
1957.
The gastric secretion of drugs: a pH partition hypothesis.
J. Pharmacol. Exp. Ther.
119:361-369 |
| 17. |
Smith, M. A., and D. I. Edwards.
1995.
The influence of microaerophilia and anaerobiosis on metronidazole uptake in Helicobacter pylori.
J. Antimicrob. Chemother.
36:453-461 |
| 18. | Stockis, A., R. Lins, X. Deroubaix, B. Jeanbaptiste, P. Calderon, and J. F. Rossignol. 1996. Nitazoxanide pharmacokinetics in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 34:349-351[Medline]. |
| 19. |
Szybalski, W., and V. Bryson.
1952.
Genetic studies on microbial cross resistance to toxic agents. I. Cross resistance of Escherichia coli to fifteen antibiotics.
J. Bacteriol.
64:489-499 |
| 19a. | Thunus, L. Personal communication. |
| 20. | Van der Hulst, R. W. M., J. J. Keller, E. A. J. Rauws, and G. N. J. Tytgat. 1996. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1:6-19[Medline]. |
| 21. |
Veldhuyzen Van Zanten, S. J. O.,
J. Goldie,
J. Hollingsworth,
C. Silletti,
H. Richardson, and R. H. Hunt.
1992.
Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori.
J. Clin. Pathol.
45:225-227 |
| 22. | Wurzer, H., L. Rodrigo, A. Archambault, T. Rokkas, N. Skandalis, R. Fedorak, F. Bazzoli, H. Hentschel, P. Mora, D. Stamler, and F. Mégraud. 1997. Short-course therapy with amoxicillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates H. pylori and heals duodenal ulcer. Aliment. Pharmacol. Ther. 11:943-952[Medline]. |
Antimicrobial Agents and Chemotherapy, November 1998, p. 2836-2840, Vol. 42, No. 11
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Vets, E., Rossignol, J.-F., Jackson, A. S.
(2009). Effects of nitazoxanide on pharmacokinetics and pharmacodynamics of a single dose of warfarin. Am J Health Syst Pharm
66: 838-842
[Abstract] [Full Text] -
Sterk, M., Muller, J., Hemphill, A., Muller, N.
(2007). Characterization of a Giardia lamblia WB C6 clone resistant to the isoflavone formononetin. Microbiology
153: 4150-4158
[Abstract] [Full Text] -
Muller, J., Sterk, M., Hemphill, A., Muller, N.
(2007). Characterization of Giardia lamblia WB C6 clones resistant to nitazoxanide and to metronidazole. J Antimicrob Chemother
60: 280-287
[Abstract] [Full Text] -
Muller, J., Wastling, J., Sanderson, S., Muller, N., Hemphill, A.
(2007). A Novel Giardia lamblia Nitroreductase, GlNR1, Interacts with Nitazoxanide and Other Thiazolides. Antimicrob. Agents Chemother.
51: 1979-1986
[Abstract] [Full Text] -
Hoffman, P. S., Sisson, G., Croxen, M. A., Welch, K., Harman, W. D., Cremades, N., Morash, M. G.
(2007). Antiparasitic Drug Nitazoxanide Inhibits the Pyruvate Oxidoreductases of Helicobacter pylori, Selected Anaerobic Bacteria and Parasites, and Campylobacter jejuni. Antimicrob. Agents Chemother.
51: 868-876
[Abstract] [Full Text] -
Muller, J., Ruhle, G., Muller, N., Rossignol, J.-F., Hemphill, A.
(2006). In Vitro Effects of Thiazolides on Giardia lamblia WB Clone C6 Cultured Axenically and in Coculture with Caco2 Cells. Antimicrob. Agents Chemother.
50: 162-170
[Abstract] [Full Text] -
Guttner, Y., Windsor, H. M., Viiala, C. H., Dusci, L., Marshall, B. J.
(2003). Nitazoxanide in Treatment of Helicobacter pylori: a Clinical and In Vitro Study. Antimicrob. Agents Chemother.
47: 3780-3783
[Abstract] [Full Text] -
Loughlin, M. F., Ala'Aldeen, D. A., Jenks, P. J.
(2003). Monotherapy with mastic does not eradicate Helicobacter pylori infection from mice. J Antimicrob Chemother
51: 367-371
[Abstract] [Full Text] -
Sisson, G., Goodwin, A., Raudonikiene, A., Hughes, N. J., Mukhopadhyay, A. K., Berg, D. E., Hoffman, P. S.
(2002). Enzymes Associated with Reductive Activation and Action of Nitazoxanide, Nitrofurans, and Metronidazole in Helicobacter pylori. Antimicrob. Agents Chemother.
46: 2116-2123
[Abstract] [Full Text] -
Adagu, I. S., Nolder, D., Warhurst, D. C., Rossignol, J.-F.
(2002). In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J Antimicrob Chemother
49: 103-111
[Abstract] [Full Text] -
Jenks, P. J., Ferrero, R. L., Tankovic, J., Thiberge, J.-M., Labigne, A.
(2000). Evaluation of Nitrofurantoin Combination Therapy of Metronidazole-Sensitive and -Resistant Helicobacter pylori Infections in Mice. Antimicrob. Agents Chemother.
44: 2623-2629
[Abstract] [Full Text] -
McVay, C. S., Rolfe, R. D.
(2000). In Vitro and In Vivo Activities of Nitazoxanide against Clostridium difficile. Antimicrob. Agents Chemother.
44: 2254-2258
[Abstract] [Full Text] -
Giacometti, A., Cirioni, O., Barchiesi, F., Ancarani, F., Scalise, G.
(2000). Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. J Antimicrob Chemother
45: 453-456
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»